Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets
Identifieur interne : 005355 ( Main/Exploration ); précédent : 005354; suivant : 005356Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets
Auteurs : Lance A. Smith ; Ariel Gordin ; Jenner [Finlande] ; C. David Marsden [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1997-11.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects), Animal, Animals, Antiparkinson agent, Behavioral disability, COMT inhibitor, Callithrix, Carbidopa, Carbidopa (therapeutic use), Catechol O-methyltransferase, Catechols (therapeutic use), Chemotherapy, Combined treatment, Decarboxylase, Dopamine Agonists (adverse effects), Dose-Response Relationship, Drug, Drug Synergism, Drug Therapy, Combination, Entacapone, Enzyme Inhibitors (therapeutic use), Enzyme inhibitor, Female, Levodopa, Levodopa (therapeutic use), Locomotion, Locomotor activity, MPTP, Male, Movement Disorders (drug therapy), Movement Disorders (etiology), Nitriles, Parkinson disease, Severity of Illness Index.
- MESH :
- chemical , adverse effects : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Dopamine Agonists.
- chemical , therapeutic use : Carbidopa, Catechols, Enzyme Inhibitors, Levodopa.
- drug therapy : Movement Disorders.
- etiology : Movement Disorders.
- Animals, Callithrix, Dose-Response Relationship, Drug, Drug Synergism, Drug Therapy, Combination, Female, Male, Nitriles, Severity of Illness Index.
Abstract
Oral administration of levodopa (L‐dopa) (2.5–25.0 mg/kg) plus carbidopa (12.5 mg/kg p.o.) to MPTP‐treated common marmosets produced a dose‐related increase in locomotor activity and a corresponding decrease in motor disability. Pretreatment with the peripheral COMT inhibitor entacapone (12.5 mg/kg p.o.) enhanced the intensity and duration of the increase in locomotor activity and the reversal of motor disability produced by a threshold dose of L‐dopa (2.5 mg/kg p.o.) plus carbidopa. By contrast, entacapone pretreatment did not potentiate the increased locomotor activity or reversal of motor disability produced by a near‐maximal dose of L‐dopa (12.5 mg/kg p.o.) plus carbidopa. The effects of entacapone (5.0–25.0 mg/kg p.o.) were dose related, with doses of >12.5 mg/kg tending to produce less potentiation of L‐dopa's effects compared to lower doses. Pretreatment with entacapone (12.5 mg/kg p.o.) without carbidopa caused a short‐lasting enhancement of L‐dopa's (12.5 mg/kg p.o.) action, whereas pretreatment with carbidopa (12.5 mg/kg p.o.) alone had a more dramatic effect. However, pretreatment with both carbidopa and entacapone produced the greatest overall motor response. In conclusion, entacapone enhances the motor response produced by a low threshold dose of L‐dopa plus carbidopa. However, optimization of both the dose of L‐dopa and entacapone appears necessary to obtain the maximal therapeutic response.
Url:
DOI: 10.1002/mds.870120616
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B51
- to stream Istex, to step Curation: 000B51
- to stream Istex, to step Checkpoint: 003979
- to stream PubMed, to step Corpus: 004563
- to stream PubMed, to step Curation: 004563
- to stream PubMed, to step Checkpoint: 004667
- to stream Ncbi, to step Merge: 004E22
- to stream Ncbi, to step Curation: 004E22
- to stream Ncbi, to step Checkpoint: 004E22
- to stream Main, to step Merge: 008384
- to stream PascalFrancis, to step Corpus: 003136
- to stream PascalFrancis, to step Curation: 003688
- to stream PascalFrancis, to step Checkpoint: 003232
- to stream Main, to step Merge: 008587
- to stream Main, to step Curation: 005355
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets</title><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name></author><author><name sortKey="Gordin, Ariel" sort="Gordin, Ariel" uniqKey="Gordin A" first="Ariel" last="Gordin">Ariel Gordin</name></author><author><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name></author><author><name sortKey="Marsden, C David" sort="Marsden, C David" uniqKey="Marsden C" first="C. David" last="Marsden">C. David Marsden</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:72FAAC5BF6A29EED81F9A337BFC2F161071D71FF</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1002/mds.870120616</idno><idno type="url">https://api.istex.fr/document/72FAAC5BF6A29EED81F9A337BFC2F161071D71FF/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B51</idno><idno type="wicri:Area/Istex/Curation">000B51</idno><idno type="wicri:Area/Istex/Checkpoint">003979</idno><idno type="wicri:doubleKey">0885-3185:1997:Smith L:entacapone:enhances:levodopa</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9399218</idno><idno type="wicri:Area/PubMed/Corpus">004563</idno><idno type="wicri:Area/PubMed/Curation">004563</idno><idno type="wicri:Area/PubMed/Checkpoint">004667</idno><idno type="wicri:Area/Ncbi/Merge">004E22</idno><idno type="wicri:Area/Ncbi/Curation">004E22</idno><idno type="wicri:Area/Ncbi/Checkpoint">004E22</idno><idno type="wicri:doubleKey">0885-3185:1997:Smith L:entacapone:enhances:levodopa</idno><idno type="wicri:Area/Main/Merge">008384</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:98-0015575</idno><idno type="wicri:Area/PascalFrancis/Corpus">003136</idno><idno type="wicri:Area/PascalFrancis/Curation">003688</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003232</idno><idno type="wicri:doubleKey">0885-3185:1997:Smith L:entacapone:enhances:levodopa</idno><idno type="wicri:Area/Main/Merge">008587</idno><idno type="wicri:Area/Main/Curation">005355</idno><idno type="wicri:Area/Main/Exploration">005355</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets</title><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name><affiliation><wicri:noCountry code="subField">England; Orion‐Farmos</wicri:noCountry></affiliation></author><author><name sortKey="Gordin, Ariel" sort="Gordin, Ariel" uniqKey="Gordin A" first="Ariel" last="Gordin">Ariel Gordin</name><affiliation><wicri:noCountry code="subField">England; Orion‐Farmos</wicri:noCountry></affiliation></author><author><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name><affiliation wicri:level="1"><country xml:lang="fr">Finlande</country><wicri:regionArea>Orion Research Center, Espoo</wicri:regionArea><wicri:noRegion>Espoo</wicri:noRegion></affiliation></author><author><name sortKey="Marsden, C David" sort="Marsden, C David" uniqKey="Marsden C" first="C. David" last="Marsden">C. David Marsden</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>University Department of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1997-11">1997-11</date><biblScope unit="vol">12</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="935">935</biblScope><biblScope unit="page" to="945">945</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">72FAAC5BF6A29EED81F9A337BFC2F161071D71FF</idno><idno type="DOI">10.1002/mds.870120616</idno><idno type="ArticleID">MDS870120616</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)</term><term>Animal</term><term>Animals</term><term>Antiparkinson agent</term><term>Behavioral disability</term><term>COMT inhibitor</term><term>Callithrix</term><term>Carbidopa</term><term>Carbidopa (therapeutic use)</term><term>Catechol O-methyltransferase</term><term>Catechols (therapeutic use)</term><term>Chemotherapy</term><term>Combined treatment</term><term>Decarboxylase</term><term>Dopamine Agonists (adverse effects)</term><term>Dose-Response Relationship, Drug</term><term>Drug Synergism</term><term>Drug Therapy, Combination</term><term>Entacapone</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Enzyme inhibitor</term><term>Female</term><term>Levodopa</term><term>Levodopa (therapeutic use)</term><term>Locomotion</term><term>Locomotor activity</term><term>MPTP</term><term>Male</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Nitriles</term><term>Parkinson disease</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Carbidopa</term><term>Catechols</term><term>Enzyme Inhibitors</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Callithrix</term><term>Dose-Response Relationship, Drug</term><term>Drug Synergism</term><term>Drug Therapy, Combination</term><term>Female</term><term>Male</term><term>Nitriles</term><term>Severity of Illness Index</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animal</term><term>Antiparkinsonien</term><term>Carbidopa</term><term>Catechol O-methyltransferase</term><term>Chimiothérapie</term><term>Decarboxylase</term><term>Entacapone</term><term>Inhibiteur enzyme</term><term>Locomotion</term><term>Lévodopa</term><term>Ouistiti</term><term>Parkinson maladie</term><term>Traitement associé</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Oral administration of levodopa (L‐dopa) (2.5–25.0 mg/kg) plus carbidopa (12.5 mg/kg p.o.) to MPTP‐treated common marmosets produced a dose‐related increase in locomotor activity and a corresponding decrease in motor disability. Pretreatment with the peripheral COMT inhibitor entacapone (12.5 mg/kg p.o.) enhanced the intensity and duration of the increase in locomotor activity and the reversal of motor disability produced by a threshold dose of L‐dopa (2.5 mg/kg p.o.) plus carbidopa. By contrast, entacapone pretreatment did not potentiate the increased locomotor activity or reversal of motor disability produced by a near‐maximal dose of L‐dopa (12.5 mg/kg p.o.) plus carbidopa. The effects of entacapone (5.0–25.0 mg/kg p.o.) were dose related, with doses of >12.5 mg/kg tending to produce less potentiation of L‐dopa's effects compared to lower doses. Pretreatment with entacapone (12.5 mg/kg p.o.) without carbidopa caused a short‐lasting enhancement of L‐dopa's (12.5 mg/kg p.o.) action, whereas pretreatment with carbidopa (12.5 mg/kg p.o.) alone had a more dramatic effect. However, pretreatment with both carbidopa and entacapone produced the greatest overall motor response. In conclusion, entacapone enhances the motor response produced by a low threshold dose of L‐dopa plus carbidopa. However, optimization of both the dose of L‐dopa and entacapone appears necessary to obtain the maximal therapeutic response.</div></front></TEI><affiliations><list><country><li>Finlande</li><li>Royaume-Uni</li></country><region><li>Angleterre</li></region></list><tree><noCountry><name sortKey="Gordin, Ariel" sort="Gordin, Ariel" uniqKey="Gordin A" first="Ariel" last="Gordin">Ariel Gordin</name><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name></noCountry><country name="Finlande"><noRegion><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Marsden, C David" sort="Marsden, C David" uniqKey="Marsden C" first="C. David" last="Marsden">C. David Marsden</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005355 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005355 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:72FAAC5BF6A29EED81F9A337BFC2F161071D71FF
|texte= Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets
}}
| This area was generated with Dilib version V0.6.23. |  |